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Background/aim: Helicobacter pylori is an important human pathogen associated with gastric and duodenal ulcers, gastric mucosaassociated lymphoid tissue lymphoma, and adenocarcinoma. Radioiodine (RAI) treatment plays an important role in the management
of differentiated thyroid cancer and primary hyperthyroidism. It is known that during RAI treatment, a considerable amount is absorbed
by the stomach as well. In this study we aimed to reveal any therapeutic impact of RAI on H. pylori infections.
Materials and methods: Eighty-seven patients who were hospitalized for RAI treatment were consecutively included in this study. Of
those, 76 patients had differentiated thyroid cancer and 11 had primary hyperthyroidism. The urea breath test (UBT) was performed on
the day before RAI, and the test was repeated after 2 months.
Results: The dose of RAI was 115 ± 3.3 mCi (range: 100–150 mCi) in the patients with malignant disease and 22.7 ± 1.4 mCi (range:
20–30 mCi) in the remaining patients. Among the patients with differentiated thyroid cancer, 44 (57%) had positive and 32 (43%)
had negative UBT tests prior to RAI. Four (36%) patients with hyperthyroidism had pretreatment positive UBT tests and 7 (64%) had
negative tests. The results of UBT conducted 2 months after RAI therapy were identical in every patient, which means that none of the
patients with positive UBT became UBT-negative (P = 1).
Conclusion: RAI does not have any therapeutic effect on H. pylori infection.
Key words: Helicobacter pylori, radioiodine therapy, differentiated thyroid cancer, urea breath test

1. Introduction
Helicobacter pylori is a gram-negative, spiral-shaped,
pathogenic bacterium that specifically colonizes the
gastric epithelium (1). The ultimate clinical manifestations
of H. pylori infection include gastric and duodenal ulcers,
gastric mucosa-associated lymphoid tissue lymphoma,
and adenocarcinoma, but most infected individuals
remain asymptomatic for life despite developing chronic
histologic gastritis (1–3). Because there is currently no
H. pylori-specific antibiotic available to cure infections,
treatment requires combining several medications. On
the other hand, during the last 2 decades, the widespread
use of certain antibiotics in the general population has
increased the occurrence of H. pylori resistance in different
countries, and H. pylori antibiotic resistance has become a
major factor leading to eradication failure (4).
Radioiodine (RAI) treatment plays an important
role in the management of differentiated thyroid cancer
* Correspondence: calperuslu@yahoo.com
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(DTC). RAI destroys any residual microscopic thyroid
carcinoma. It also facilitates follow-up and early detection
of recurrent or metastatic disease by measurement of
serum thyroglobulin (5). Isotope therapy is one of the
methods also used in treating primary hyperthyroidism.
Indications for RAI therapy in Graves–Basedow disease
include recurrent hyperthyroidism after thyrostatic
treatment or thyroidectomy and side effects observed
during thyrostatic treatment. In toxic nodules, isotope
therapy is the first choice of therapies (6).
During isotope treatment, RAI is distributed
throughout the normal tissues, which possess sodium/
iodine (Na/I) symporters, as well as malignant tissues, and
a considerable amount is absorbed by the stomach (7,8).
On the basis of this observation, a group of researchers
previously questioned whether the effect of the high
radiation induced by RAI in the stomach is effective in
the eradication of H. pylori infections, and they showed a
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suppressive effect (9). In this study we aimed to reveal any
therapeutic impact of RAI on H. pylori infection.
2. Materials and methods
Eighty-seven patients who were hospitalized in our
Nuclear Medicine Department for RAI treatment
were consecutively included in this study between
January 2011 and January 2012. Exclusion criteria
included previous eradication therapy or use of bismuth
compounds, antibiotics, and antisecretory drugs within
the last 2 months. Females who might be pregnant (as
a contraindication for RAI therapy) and patients with
hepatobiliary, pulmonary, or metabolic diseases; previous
gastric surgery; or dyspepsia were also excluded. The
Ankara Atatürk Education and Research Hospital Ethics
Committee for Human Studies approved the protocol,
and all participants provided informed consent. The urea
breath test (UBT) was performed for all patients on the day
before RAI therapy. The UBT was repeated 2 months after
RAI administration, a period during which patients were
advised not to consume bismuth compounds, antibiotics,
or antisecretory drugs.
During the urea breath test, patients swallowed 37 kBq
(1 µCi) of an encapsulated form of 14C-urea/citric acid
(Helica Noster System, Stockholm, Sweden) in 25 mL of
water after overnight fasting. Breath samples were collected
with a special dry cartridge system (Heliprobe BreathCard;
Noster System) after 10 min. Patients exhaled gently into
the cartridge mouthpiece until the indicator membrane
changed color from orange to yellow. The BreathCard
was inserted into a special small desktop Geiger–Müller
counter (Heliprobe Analyzer; Noster System), and activity
was counted for 250 s. Results were expressed both as
counts per min (cpm) and as grade (0: not infected, <25
cpm; 1: equivocal, 25–50 cpm; 2: infected, >50 cpm), as
suggested by the manufacturer according to the counts
obtained from the cartridges.
Descriptive statistics were generated for all study
variables, including mean and standard deviation for
continuous variables and relative frequencies for categorical

variables. Relations between subgroups were analyzed
by using the chi-square test for categorical variables and
the t-test for continuous variables. One-sided values of P
< 0.05 were considered statistically significant. SPSS 15.0
for Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis.
3. Results
Of the 87 patients who underwent RAI treatment, 76
had DTC and 11 patients had hyperthyroidism. The
dose of RAI was 115 ± 3.3 mCi (range: 100–150 mCi) in
the patients with malignant disease and 22.7 ± 1.4 mCi
(range: 20–30 mCi) in the remaining patients. Among the
patients with DTC, 44 (57%) had positive and 32 (43%)
had negative UBT tests prior to RAI. Four (36%) patients
with hyperthyroidism had pretreatment positive UBTs and
7 (64%) had negative tests. The results of UBT 2 months
after RAI therapy were identical in every patient, which
means that none of the patients with positive UBT became
UBT-negative (P = 1, Table).
4. Discussion
H. pylori eradication failure is an important problem. The
main reasons for eradication failure are antibiotic resistance,
poor compliance with antibiotic regimens, and rapid
metabolism of proton pump inhibitors (PPI) (10). Triple
treatment, including PPI-clarithromycin and amoxicillin
or metronidazole, was once the first-line treatment
throughout the world (11). However, this combination has
lost some efficacy and often leads to the cure of only 70%
of the patients (10). The background rate of clarithromycin
resistance is critically important because it is associated
with the failure of standard triple therapy (12). For this
reason, bismuth-containing quadruple therapies are
recommended for first-line empirical treatments in areas
of high clarithromycin resistance (>15%–20%), according
to the Maastricht IV consensus report (13). If this regimen
is not available, sequential treatment or a nonbismuth
quadruple therapy is recommended.

Table. The results of urea breath tests (UBTs) in patients admitted for radioiodine (RAI)
treatment.
UBT after RAI therapy

Total

Positive

Negative

Positive

46

-

46

Negative

-

39

39

Total

46

39

85

UBT before RAI therapy
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The antibiotic treatment of H. pylori infections carries
some risk. Patients frequently experience side effects, which
include metallic taste in the mouth, flushing, headache,
nausea, vomiting, diarrhea, constipation, and stomach
cramps (2,14). Antibiotics can enable the overgrowth
of Candida albicans, which can result in vaginitis or
other complaints. In addition, antibiotic therapy can be
complicated by the development of pseudomembranous
colitis. Moreover, antibiotic treatment could lead to the
overgrowth of antibiotic-resistant strains of H. pylori.
For these reasons, the search continues for alternatives
to the conventional triple therapy treatment for H. pylori
infections.
At present, the most promising natural treatment is a
mixture of black currant seed oil and fish oil. A study showed
that this mixture can eradicate H. pylori in 20% of cases (15).
In addition, certain probiotics and prebiotics had efficacy as
an adjuvant treatment in reducing side effects, and, in this
way, they may indirectly improve the therapeutic success
(16). Mastic gum has been shown to promote the healing
of duodenal ulcers in vitro (17). Vitamin C and berberine
suppress H. pylori temporarily in some patients (18,19).
To date, none of the alternative therapies, however, have
clear-cut scientific evidence to be acceptable alternatives to
conventional antibiotic regimens (20).
RAI is widely used in the treatment of DTC and,
to a lesser extent, in hyperthyroidism. Following RAI
therapy, a considerable amount of the extrathyroidal
iodide (15%) is located in the stomach (21). The residence
time of radioactive iodine in the stomach is 1.23 ± 0.31
h (0.84–1.62 h) in the euthyroid state and 0.9 ± 0.08 h
(0.82–1.04 h) in the hyperthyroid state, which may be
long enough to have marked biologic or therapeutic
effects (21). Although RAI therapy is not a logical method
for treatment in patients suffering from H. pylori, it can
be potentially used in the food industry to sterilize food.
Based on these facts, Gholamrezanezhad et al. investigated

whether the high radiation induced by RAI in the stomach
is effective in the eradication of H. pylori infections (22).
They showed a significant reduction in the number of
positive UBT results in a group of patients with DTC
who underwent RAI treatment (32.4% of UBT-positive
cases became UBT-negative). The authors concluded
that their findings provided an indirect piece of evidence
about the radiosensitivity of the bacteria and could have
future clinical applications (22). Our findings, which show
identical UBT results despite RAI administration, do not
support the conclusion of the study by Gholamrezanezhad
et al. Our search in the scientific banks of MEDLINE and
EMBASE found no trials evaluating the beneficial effects
of RAI therapy on any infectious disorders, including H.
pylori, except for the above-mentioned series (22). There
was also no hypothesis regarding the mechanism of the
possible therapeutic effect of RAI on H. pylori. The authors
speculated that RAI causes intermittent gastritis with the
subsequent reduction of acid secretion and, therefore,
reduced sensitivity of the UBT. Hence, they suggested
that radioactive iodine might have suppressed the H.
pylori infection and made the results of the UBT false
negative (22). We disagree with the authors because if this
hypothesis were true, we would have seen at least one case
of a negative UBT after RAI in our series. In order to rule
out the possibility of a false negative UBT, an ideal study
would include a second diagnostic method for H. pylori.
We think that the main reason for the post-RAI therapy
negative UBTs in this series may be noncompliance
with the antibiotic and PPI-free period. Our studies also
showed that the dose of RAI has no association with H.
pylori eradication, as no single UBT became negative after
high or low doses of RAI.
In conclusion, our study revealed that RAI does not
have any therapeutic effect on H. pylori infection. Future
studies of this topic should involve animal subjects and a
second diagnostic method for H. pylori, ideally histology.
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